Gartner A, Dorfel D, Diers K, Witt S, Strobel A, Brocke B
Eur Arch Psychiatry Clin Neurosci. 2018; 269(2):209-221.
PMID: 30291441
DOI: 10.1007/s00406-018-0944-9.
Duncan K, Otrubova K, Boger D
Bioorg Med Chem. 2014; 22(9):2763-70.
PMID: 24690529
PMC: 4029506.
DOI: 10.1016/j.bmc.2014.03.013.
Otrubova K, Cravatt B, Boger D
J Med Chem. 2014; 57(3):1079-89.
PMID: 24456116
PMC: 3940414.
DOI: 10.1021/jm401820q.
Otrubova K, Brown M, McCormick M, Han G, ONeal S, Cravatt B
J Am Chem Soc. 2013; 135(16):6289-99.
PMID: 23581831
PMC: 3678763.
DOI: 10.1021/ja4014997.
Han B, Wright R, Kirchhoff A, Chester J, Cooper B, Davisson V
Anal Biochem. 2012; 432(2):74-81.
PMID: 23044255
PMC: 3760509.
DOI: 10.1016/j.ab.2012.09.031.
The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH).
Otrubova K, Ezzili C, Boger D
Bioorg Med Chem Lett. 2011; 21(16):4674-85.
PMID: 21764305
PMC: 3146581.
DOI: 10.1016/j.bmcl.2011.06.096.
Reversible competitive α-ketoheterocycle inhibitors of fatty acid amide hydrolase containing additional conformational constraints in the acyl side chain: orally active, long-acting analgesics.
Ezzili C, Mileni M, McGlinchey N, Long J, Kinsey S, Hochstatter D
J Med Chem. 2011; 54(8):2805-22.
PMID: 21428410
PMC: 3085948.
DOI: 10.1021/jm101597x.
Fluoride-mediated capture of a noncovalent bound state of a reversible covalent enzyme inhibitor: X-ray crystallographic analysis of an exceptionally potent α-ketoheterocycle inhibitor of fatty acid amide hydrolase.
Mileni M, Garfunkle J, Ezzili C, Cravatt B, Stevens R, Boger D
J Am Chem Soc. 2011; 133(11):4092-100.
PMID: 21355555
PMC: 3060301.
DOI: 10.1021/ja110877y.
X-ray crystallographic analysis of alpha-ketoheterocycle inhibitors bound to a humanized variant of fatty acid amide hydrolase.
Mileni M, Garfunkle J, Ezzili C, Kimball F, Cravatt B, Stevens R
J Med Chem. 2009; 53(1):230-40.
PMID: 19924997
PMC: 2804032.
DOI: 10.1021/jm9012196.
Identification of intracellular carriers for the endocannabinoid anandamide.
Kaczocha M, Glaser S, Deutsch D
Proc Natl Acad Sci U S A. 2009; 106(15):6375-80.
PMID: 19307565
PMC: 2669397.
DOI: 10.1073/pnas.0901515106.
Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling.
Hoover H, Blankman J, Niessen S, Cravatt B
Bioorg Med Chem Lett. 2008; 18(22):5838-41.
PMID: 18657971
PMC: 2634297.
DOI: 10.1016/j.bmcl.2008.06.091.
Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hydrolase.
DeMartino J, Garfunkle J, Hochstatter D, Cravatt B, Boger D
Bioorg Med Chem Lett. 2008; 18(22):5842-6.
PMID: 18639454
PMC: 2582052.
DOI: 10.1016/j.bmcl.2008.06.084.
Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase.
Garfunkle J, Ezzili C, Rayl T, Hochstatter D, Hwang I, Boger D
J Med Chem. 2008; 51(15):4392-403.
PMID: 18630870
PMC: 2556205.
DOI: 10.1021/jm800136b.
Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates.
Mor M, Lodola A, Rivara S, Vacondio F, Duranti A, Tontini A
J Med Chem. 2008; 51(12):3487-98.
PMID: 18507372
PMC: 3744893.
DOI: 10.1021/jm701631z.
Enzymatic pathways that regulate endocannabinoid signaling in the nervous system.
Ahn K, McKinney M, Cravatt B
Chem Rev. 2008; 108(5):1687-707.
PMID: 18429637
PMC: 3150828.
DOI: 10.1021/cr0782067.
Optimization of alpha-ketooxazole inhibitors of fatty acid amide hydrolase.
Kimball F, Romero F, Ezzili C, Garfunkle J, Rayl T, Hochstatter D
J Med Chem. 2008; 51(4):937-47.
PMID: 18247553
PMC: 2734917.
DOI: 10.1021/jm701210y.
A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol.
Blankman J, Simon G, Cravatt B
Chem Biol. 2007; 14(12):1347-56.
PMID: 18096503
PMC: 2692834.
DOI: 10.1016/j.chembiol.2007.11.006.
Structure-activity relationships of alpha-ketooxazole inhibitors of fatty acid amide hydrolase.
Hardouin C, Kelso M, Romero F, Rayl T, Leung D, Hwang I
J Med Chem. 2007; 50(14):3359-68.
PMID: 17559203
PMC: 2531194.
DOI: 10.1021/jm061414r.
The 'specific' tyrosine kinase inhibitor genistein inhibits the enzymic hydrolysis of anandamide: implications for anandamide uptake.
Thors L, Alajakku K, Fowler C
Br J Pharmacol. 2007; 150(7):951-60.
PMID: 17325653
PMC: 2013877.
DOI: 10.1038/sj.bjp.0707172.
Potent and selective alpha-ketoheterocycle-based inhibitors of the anandamide and oleamide catabolizing enzyme, fatty acid amide hydrolase.
Romero F, Du W, Hwang I, Rayl T, Kimball F, Leung D
J Med Chem. 2007; 50(5):1058-68.
PMID: 17279740
PMC: 2531193.
DOI: 10.1021/jm0611509.
